Skip to main content
Contact Us
Subscribe
E-Edition
56°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Travere Therapeutics Inc
(NQ:
TVTX
)
18.25
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
28
Open
18.25
Bid (Size)
18.01 (1)
Ask (Size)
19.95 (1)
Prev. Close
18.25
Today's Range
18.25 - 18.25
52wk Range
5.120 - 20.33
Shares Outstanding
60,717,176
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 13, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
November 12, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Performance
YTD
+90.90%
+90.90%
1 Month
+4.11%
+4.11%
3 Month
+101.66%
+101.66%
6 Month
+169.97%
+169.97%
1 Year
+209.85%
+209.85%
More News
Read More
3 Under-the-Radar Healthcare Companies
November 11, 2024
Via
MarketBeat
A Preview Of Travere Therapeutics's Earnings
October 30, 2024
Via
Benzinga
Travere Therapeutics Stock: A Deep Dive Into Analyst Perspectives (24 Ratings)
October 21, 2024
Via
Benzinga
Breaking Down Travere Therapeutics: 23 Analysts Share Their Views
October 16, 2024
Via
Benzinga
Travere Therapeutics Announces Pricing of Public Offering of Common Stock
November 07, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Announces Proposed Public Offering of Common Stock
November 07, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present at Upcoming Investor Conferences
November 04, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs
October 10, 2024
Via
Benzinga
Where Travere Therapeutics Stands With Analysts
September 27, 2024
Via
Benzinga
Travere Therapeutics Reports Third Quarter 2024 Financial Results
October 31, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024
October 26, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Jim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It Up'; Warns That Travere Therapeutics Is Losing A 'Ton Of Money'
October 23, 2024
Via
Benzinga
Travere Therapeutics to Report Third Quarter 2024 Financial Results
October 21, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
October 17, 2024
Via
Benzinga
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
October 17, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024
October 14, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
TVTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Travere Therapeutics, Inc. and Encourages Investors to Contact the Firm
October 11, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Travere Therapeutics Hits 14-Month High On A Promising FDA 'Pivot' In Kidney Disease
October 09, 2024
Via
Investor's Business Daily
Exposures
Product Safety
Micron To $150? Here Are 10 Top Analyst Forecasts For Friday
September 27, 2024
Via
Benzinga
Costco, Scholastic And 3 Stocks To Watch Heading Into Friday
September 27, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
September 26, 2024
Via
Benzinga
Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up
September 26, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 12, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
